|View printer-friendly version|
|June 14, 2006 1:48 p.m.|
|Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets|
Jerusalem, Israel,, June 14, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application ("ANDA") for Losartan Potassium and Hydrochlorothiazide Tablets, 50 mg/12.5 mg and 100 mg/25 mg. Final approval is expected upon expiration of patent protection in April 2010.